FGF21 and Hepatic steatosis: The administration of doses of 5 × 1010 vg/mouse or higher of FGF21‐encoding vectors completely prevented the development of hepatic steatosis (Fig 7F), which correlated with the weight of the organ (Appendix Fig S7D) and its total triglyceride and cholesterol content (Appendix Fig S7E and F).